Icotrokinra Sustains Skin Clearance at High-Impact Psoriasis Sites Through 2 Years

Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost clear skin at week 112, Johnson & Johnson announced.¹ The late-breaking data from the phase 3 ICONIC-TOTAL trial (NCT06095102) were presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress. The once-daily oral peptide, which blocks the interleukin (IL)-23 receptor, was approved by the FDA in March 2026 for moderate to severe plaque psoriasis in adults and adolescents 12 years and older weighing at least 40 kg.²

ICONIC-TOTAL Results Through Week 112

The proportion of patients with an Investigator's Global Assessment (IGA) score of 0/1 rose from 57% at week 16 to 67% at week 24 and 70% at week 112. Complete site-specific clearance at week 112 was reported in 60% of patients with scalp psoriasis (scalp-specific IGA score of 0), 89% with genital psoriasis (static Physician's Global Assessment of Genitalia score of 0), and 63% with hand and/or foot psoriasis (Physician's Global Assessment of Hands and Feet score of 0).¹

Nail disease continued to improve with longer treatment. Mean percentage improvement on the modified Nail Psoriasis Severity Index was 33% at week 16, 62% at week 52, and 71% at week 112. No new safety signals were identified, and findings were consistent with the established safety profile.

"These robust two-year data validate that Icotyde provides enduring skin clearance with a favorable safety profile, making it a pivotal advancement in plaque psoriasis treatment," Richard B. Warren, MD, PhD, professor of dermatology at the University of Manchester, said in a press statement. Warren was a clinical investigator on the ICONIC-TOTAL study.

Study Design and Patient Population

ICONIC-TOTAL enrolled adults and adolescents with at least moderate psoriasis involving 1 or more high-impact sites (ie, scalp, genitals, and/or hands and feet). Participants were randomly assigned to once-daily icotrokinra or placebo, and those receiving placebo transitioned to icotrokinra at week 16.

The primary end point was an IGA score of 0/1 with at least a 2-grade improvement from baseline. In the week 16 analysis, 57% of patients receiving icotrokinra met that end point vs 6% receiving placebo (P < .001).³

What's Next for Icotrokinra?

The 2-year findings add to 52-week data from the ICONIC-LEAD study presented at the 2026 American Academy of Dermatology Annual Meeting. Phase 3 studies are also underway in psoriatic arthritis (ICONIC-PsA 1 and 2), ulcerative colitis (ICONIC-UC), and Crohn disease (ICONIC-CD).¹

David M. Lee, MD, PhD, global immunology therapeutic area head at Johnson & Johnson, echoed the importance of the new data. “Availability of long-term data are vital for informing the treatment of plaque psoriasis including particularly challenging areas of the body where conventional treatments may fall short,” he said in a statement to the press. "These two-year Icotyde results empower physicians to treat high-impact sites, knowing that data support sustained clinical outcomes for patients."

Follow our EADV conference page for more late breaking data and expert insights on advances in dermatology.

References

1. Johnson & Johnson announces new Icotyde (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy. Press release. Johnson & Johnson. October 2, 2026. Accessed October 2, 2026. https://www.jnj.com/media-center/press-releases/...
2. Hebebrand M. FDA approves icotrokinra, first oral IL-23 receptor blocker for psoriasis. Dermatology Times. March 18, 2026. Accessed October 2, 2026. https://www.dermatologytimes.com/view/fda-approves-ictrokinra-first-oral-il-23-receptor-blocker-for-psoriasis
3. Hebebrand M. Icotrokinra effective in high-impact psoriasis areas. Dermatology Times. May 9, 2025. Accessed October 2, 2026. https://www.dermatologytimes.com/view/icotrokinra-effective-in-high-impact-psoriasis-areas